Mr. Stephen Van Deventer reports

PREVECEUTICAL ENGAGES PHOENIX CORPORATE FINANCE INC. TO PROVIDE ADVISORY SERVICES

Preveceutical Medical Inc. has engaged Toronto-based Phoenix Corporate Finance Inc. as its advisory firm to provide strategic and corporate advisory services relating to potential future transactions.

Pursuant to the engagement, Phoenix has agreed to provide corporate advisory services to the company with respect to one or more potential strategic transactions, including the potential acquisition or disposition of assets. As consideration for the services, the company has agreed to pay Phoenix an aggregate of $30,000 plus applicable taxes.

Stephen Van Deventer, chairman and chief executive officer, commented: "As Preveceutical transitions from [research and development] into the clinical phase, we believe moving forward will require strategic partnerships and an evolution as to how we approach each of our four research programs. Over the coming months, we will dedicate additional resources and human talent to each of the different programs that are specific to the medical field of each therapy."

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.